Moreover, the co-occurrence of HER2 mutation and amplification was rare (only in 10 tumor types), with a proportion of 0.26% (24 of 9184 patients) in the overall cohort consisting of tumor types carrying HER2 mutation or amplification (Figure 1G). This evidence concerns the gene ERBB2 and neoplasm.